You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Drug Price Trends for LEVALBUTEROL CONC


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for LEVALBUTEROL CONC

Average Pharmacy Cost for LEVALBUTEROL CONC

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
LEVALBUTEROL CONC 1.25 MG/0.5 00378-6993-93 4.13897 EACH 2025-01-22
LEVALBUTEROL CONC 1.25 MG/0.5 00378-6993-93 3.99257 EACH 2024-12-18
LEVALBUTEROL CONC 1.25 MG/0.5 00378-6993-93 4.13722 EACH 2024-11-20
LEVALBUTEROL CONC 1.25 MG/0.5 00378-6993-93 3.69978 EACH 2024-10-23
LEVALBUTEROL CONC 1.25 MG/0.5 00093-4147-56 3.69978 EACH 2024-10-23
LEVALBUTEROL CONC 1.25 MG/0.5 00093-4147-56 3.84996 EACH 2024-09-18
LEVALBUTEROL CONC 1.25 MG/0.5 00378-6993-93 3.84996 EACH 2024-09-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Levalbuterol

Introduction to Levalbuterol

Levalbuterol, a short-acting β2-agonist (SABA), is widely used for the treatment and prevention of asthma exacerbations. It is available under brand names such as Xopenex HFA and in various generic forms. Here, we will delve into the market analysis and price projections for levalbuterol, considering its usage, market trends, and economic impact.

Market Size and Growth

The global asthma drugs market, within which levalbuterol is a significant player, is projected to experience substantial growth. As of 2023, the U.S. asthma drugs market was valued at USD 8.95 billion and is expected to surpass USD 14.75 billion by 2033, with a CAGR of 5.12% from 2024 to 2033[3].

Segment Analysis

The market for levalbuterol can be segmented based on several factors:

By Type

Levalbuterol is available in different formulations, including inhalation aerosols and inhalation solutions. The inhalation solution is commonly used and comes in various concentrations such as 0.31 mg/3 mL, 0.63 mg/3 mL, and 1.25 mg/0.5 mL[2][5].

By Region

North America, particularly the United States, dominates the global asthma drugs market with the highest market share. This region is expected to continue its dominance due to the high prevalence of asthma and advanced healthcare infrastructure[3].

By Patient Segment

The adult segment is the largest in the U.S. asthma drugs market and is expected to maintain its leadership throughout the forecast period. However, the pediatric segment also holds significant promise due to the need for personalized medication plans and the effectiveness of inhaled corticosteroids in children[3].

Price Analysis

The prices of levalbuterol vary based on the formulation, concentration, and quantity.

Inhalation Solution Prices

  • For a 0.31 mg/3 mL concentration, the cost is around $52 for a supply of 75 milliliters.
  • For a 0.63 mg/3 mL concentration, the cost is approximately $137 for a supply of 72 milliliters.
  • For a 1.25 mg/0.5 mL concentration, the cost is around $163.42 for 30 solutions[2][5].

Generic and Brand Name Prices

Generic versions of levalbuterol are available and often cheaper than brand-name versions like Xopenex. For example, a generic version of the 0.63 mg/3 mL concentration can cost as low as $56.90 for 72 milliliters[5].

Economic Impact

The inclusion of levalbuterol in national reimbursement drug lists can have a significant economic impact. For instance, a study in China found that preserving levalbuterol in the National Reimbursement Drug List (NRDL) resulted in cost savings of ¥82.8 million over three years due to reduced hospital stays and other healthcare costs[4].

Market Trends and Drivers

Rising Prevalence of Asthma

The increasing prevalence of asthma, affecting approximately 25 million individuals in the United States, is a major driver of the market. The annual cost of asthma in the U.S. is estimated at around $56 billion, with direct costs primarily stemming from hospital stays[3].

Approval of New Treatments

The approval of new treatments like Airsupra (albuterol/budesonide) marks significant advancements in asthma management. Airsupra has shown efficacy in reducing severe asthma attacks and minimizing systemic corticosteroid exposure, which could influence the demand for levalbuterol and other asthma medications[3].

Technological Advancements

Technological advancements in inhaler devices, such as the introduction of pressurized metered-dose inhalers (pMDIs), are expected to enhance patient compliance and treatment outcomes, potentially impacting the market for levalbuterol[3].

Challenges and Restraints

Financial Barriers

Despite the growth potential, financial barriers, including high medication costs and limited access to healthcare, especially for low-income individuals, can restrict the market growth. The lack of health insurance among some asthma sufferers exacerbates these challenges[3].

Regulatory Changes

Changes in regulatory status, such as inclusion or withdrawal from national reimbursement drug lists, can significantly impact the market. For example, the status change of levalbuterol in China's NRDL had substantial economic implications[4].

Competitive Analysis

The market for levalbuterol is competitive, with several pharmaceutical companies offering both brand-name and generic versions. Key competitors include manufacturers of Xopenex and other generic levalbuterol products. The competitive landscape is influenced by factors such as pricing, product formulation, and regulatory approvals[1][5].

Forecast and CAGR

The global asthma drugs market, including levalbuterol, is expected to grow at a CAGR of 5.09% from 2024 to 2033. This growth is driven by increasing demand, advancements in treatment options, and the rising prevalence of asthma[3].

Key Takeaways

  • Market Growth: The U.S. asthma drugs market, including levalbuterol, is projected to grow significantly, reaching USD 14.75 billion by 2033.
  • Price Variability: Prices for levalbuterol vary widely based on formulation and concentration, with generic versions often being more affordable.
  • Economic Impact: Inclusion in national reimbursement drug lists can lead to substantial cost savings.
  • Market Drivers: Rising asthma prevalence, new treatment approvals, and technological advancements drive the market.
  • Challenges: Financial barriers and regulatory changes can impact market growth.

FAQs

1. What is the primary use of levalbuterol? Levalbuterol is primarily used for the treatment and prevention of asthma exacerbations.

2. How does the price of levalbuterol vary? The price of levalbuterol varies based on the formulation, concentration, and quantity. For example, a 0.31 mg/3 mL concentration can cost around $52 for 75 milliliters, while a 1.25 mg/0.5 mL concentration can cost around $163.42 for 30 solutions.

3. What is the impact of levalbuterol on healthcare costs? Studies have shown that the inclusion of levalbuterol in national reimbursement drug lists can lead to significant cost savings due to reduced hospital stays and other healthcare costs.

4. Which region dominates the global asthma drugs market? North America, particularly the United States, dominates the global asthma drugs market with the highest market share.

5. What are the key drivers of the levalbuterol market? Key drivers include the rising prevalence of asthma, approvals of new treatments, and technological advancements in inhaler devices.

Sources

  1. Cognitivemarketresearch.com: Levalbuterol Market Report 2024 (Global Edition)
  2. Drugs.com: Levalbuterol Prices, Coupons, Copay Cards & Patient Assistance
  3. Biospace.com: U.S. Asthma Drugs Market Size to Surpass USD 14.75 Bn by 2033
  4. Pubmed.ncbi.nlm.nih.gov: Estimating the Economic Impact of Levalbuterol's Potential Status Change Within and Withdrawal From the NRDL in Treating Pediatric Asthma
  5. Drugs.com: Xopenex Prices, Coupons, Copay Cards & Patient Assistance

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.